- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02999490
18F-FDG PET/CT in Diagnostic Patients of Disorder of Consciousness
April 19, 2018 updated by: Jing Zhao, Guangzhou General Hospital of Guangzhou Military Command
Clinical examinations are difficult to discriminate between vegetative state and minimally conscious state.
the diagnostic and prognostic usefulness of neuroimaging methods has not been established in a clinical setting.
we will do a forward study of PET imaging in disorders of consciousness patients, and validate with clinical assessments with the coma recovery Scale-Revised(CRS-R).
Study Overview
Detailed Description
Every patient need to be conducted the PET/CT scanning two times.The first time is resting state.The second time is stimulated state by watching a vedio.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- The PET/CT Centre Guangzhou General Hospital of Guangzhou Military Command
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years to 75 years (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Clinical diagnosis of disorder of consciousness
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Controls
The controls are intravenous injected of 185 to 370 MBq 18F-FDG.Then,the controls sleep for an hour in a quiet room before scanning.
|
|
EXPERIMENTAL: Patients
The patients are intravenous injected of 185 to 370 MBq 18F-FDG.Then,the patients sleep for an hour in a quiet room before scanning.
|
18F-FDG is positron emission tomography imaging agent which is already widely used in PET/CT examination.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
standardized uptake value
Time Frame: 60 mins after injecting 18F-FDG
|
60 mins after injecting 18F-FDG
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Yin Jilin
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2016
Primary Completion (ACTUAL)
December 1, 2017
Study Completion (ACTUAL)
December 5, 2017
Study Registration Dates
First Submitted
March 25, 2016
First Submitted That Met QC Criteria
December 20, 2016
First Posted (ESTIMATE)
December 21, 2016
Study Record Updates
Last Update Posted (ACTUAL)
April 20, 2018
Last Update Submitted That Met QC Criteria
April 19, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Brain Damage, Chronic
- Unconsciousness
- Consciousness Disorders
- Persistent Vegetative State
- Molecular Mechanisms of Pharmacological Action
- Radiopharmaceuticals
- Fluorodeoxyglucose F18
Other Study ID Numbers
- HYXK0001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Persistent Vegetative State
-
Hadassah Medical OrganizationWithdrawnChronic Vegetative State
-
Hadassah Medical OrganizationSuspendedChronic Vegetative StateIsrael
-
IRCCS San Camillo, Venezia, ItalyCompletedMinimally Conscious State | Vegetative StateItaly
-
Hangzhou Normal UniversityCompletedMinimally Conscious State | Vegetative State
-
Hangzhou Normal UniversityCompleted
-
Jing WangCompletedMinimally Conscious State | Vegetative StateChina
-
Hangzhou Normal UniversityCompletedMinimally Conscious State | Vegetative StateChina
-
Hangzhou Normal UniversityCompletedMinimally Conscious State | Vegetative StateChina
-
IRCCS Policlinico S. MatteoUnknownMinimally Conscious State | Vegetative StateItaly
-
Hangzhou Normal UniversityCompletedBrain Diseases | Central Nervous System Diseases | Unconsciousness | Vegetative StateChina
Clinical Trials on 18F-FDG
-
Affiliated Hospital of Jiangnan UniversityRecruitingPositron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor EfficacySolid Tumor | Breast Cancer Stage II | Breast Cancer Stage IIIChina
-
Turku University HospitalCompleted
-
Tim LauMcGill UniversityNot yet recruitingCognitive Impairment | Dementia | Dementia With Lewy Bodies
-
Hospices Civils de LyonCompleted
-
First Hospital of China Medical UniversityRecruiting
-
Avid RadiopharmaceuticalsCompletedFrontotemporal Dementia | Alzheimer's DiseaseUnited Kingdom
-
Andrei IagaruNational Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Metastatic Renal Cell Cancer | Stage III Renal Cell Cancer | Stage IV Non-Small Cell Lung Cancer | Stage IV Breast Cancer | B-Cell Neoplasm | Stage IIIA Breast Cancer | Stage IV Renal Cell Cancer | Stage IIIC Breast Cancer | Estrogen... and other conditionsUnited States
-
University of UtahActive, not recruiting
-
University of Alabama at BirminghamRecruitingHER2-positive Breast CancerUnited States
-
Stanford UniversityNot yet recruiting